Han Myint

Han Myint, MD is the current Chief Medical Officer at NextCure. Dr. Myint has over two decades of experience in the field of hematology and oncology.

Han began their career as a member of IFIG (1997-2001), before moving on to Rush University Medical Center as Director of the Hem/Onc Fellowship Program (2001-2005). From there, they went to the University of Colorado Denver as Director of the Hematological Malignancies and Stem Cell Transplant Program (2005-2012).

In 2012, Dr. Myint joined Cell Therapeutics, Inc. as Senior Vice President of Medical Affairs (2012-2013). The following year, they became Vice President of Global Medical Affairs for Celgene (2013-2020), where they oversaw clinical development programs for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Most recently, Dr. Myint served as Chief Medical Officer at NexImmune, Inc. (2020-2021) before taking on their current role at NextCure. Throughout their career, they have played a critical role in the development and commercialization of multiple hematologic therapies.